<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="285">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04370808</url>
  </required_header>
  <id_info>
    <org_study_id>VITACOV</org_study_id>
    <nct_id>NCT04370808</nct_id>
  </id_info>
  <brief_title>VITACOV: Vitamin D Polymorphisms and Severity of COVID-19 Infection</brief_title>
  <acronym>VITACOV</acronym>
  <official_title>VITACOV: Vitamin D-related Polymorphisms and Vitamin D Levels as Risk Biomarkers of COVID-19 Infection Severity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Lisbon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cardiovascular Centre of Universidade de Lisboa (CCUL)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Faculty of Medicine of Universidade de Lisboa (FMUL)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro Hospitalar Universitário Lisboa Norte (CHULN)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro Hospitalar Universitário São João (CHUSJ)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CINTESIS - Center for Health Technology and Services Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NOVA Medical School of Universidade NOVA de Lisboa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>HeartGenetics, Genetics and Biotechnology SA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Gulbenkian de Ciência (IGC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Lisbon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin D deficiency has been linked to hypertension, autoimmune, infectious and
      cardiovascular diseases which are risk factors for COVID-19. Moreover, COVID-19 patients have
      a very high prevalence of hypovitaminosis D (Turin data). Taken together, we aim to
      investigate whether genetic variants in vitamin D-related genes contribute to a poor COVID-19
      outcome, particularly in hypertension and CV patients, proposing thus a personalized
      therapeutics based on vitamin D supplementation in order to reduce the severity and deaths.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Collected data from Turin University indicate that hospitalized patients have a very high
      prevalence of hypovitaminosis D. Reports from China and Italy show that hypertension presents
      an increased risk of COVID-19-related death. Otherwise, observational studies suggest that
      25(OH)D induces protection against respiratory pathogens while large-scale studies indicate
      that serum 25(OH)D-level is inversely correlated to hypertension prevalence. Recent published
      data (2020) shows that 66% of Portuguese adults present Vitamin D deficiency. HeartGenetics'
      genetic database with more than 8.500 Portuguese genotypes shows that the prevalence of
      vitamin D polymorphisms in this population is 4-fold higher than the EU average, increasing
      the risk of hypovitaminosis D.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in vitamin D blood levels between COVID-19 patients with different degrees of disease severity.</measure>
    <time_frame>Blood samples of COVID-19 patients will be collected at baseline (after subject enrollment; single point collection).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Differences in genetic variants in vitamin D-related genes between COVID-19 patients with different degrees of disease severity.</measure>
    <time_frame>Blood samples of COVID-19 patients will be collected at baseline (after subject enrollment; single point collection).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences in vitamin D blood levels between COVID-19 patients in relation to mortality.</measure>
    <time_frame>Through study completion, an average of 3 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in vitamin D blood levels between COVID-19 patients in relation to length of stay in hospitals.</measure>
    <time_frame>Through study completion, an average of 3 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in vitamin D blood levels between COVID-19 patients in relation to duration of mechanical ventilation.</measure>
    <time_frame>Through study completion, an average of 3 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to mortality.</measure>
    <time_frame>Through study completion, an average of 3 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to length of stay in hospitals.</measure>
    <time_frame>Through study completion, an average of 1 year.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to duration of mechanical ventilation.</measure>
    <time_frame>Through study completion, an average of 3 months.</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Mild to severe disease</arm_group_label>
    <description>Mild to severe disease (admission to isolation room)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Critical patients</arm_group_label>
    <description>Critical patients (admission to ICU)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exposure</intervention_name>
    <description>Individuals with SARS-CoV-2 exposure and COVID-19 symptoms.</description>
    <arm_group_label>Critical patients</arm_group_label>
    <arm_group_label>Mild to severe disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        COVID-19 patients admitted to hospitals from Lisbon and Oporto.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults of 18 years and above.

          -  COVID-19 patients admitted with mild to severe disease (admission to isolation room)
             or critical patients (admission to ICU).

          -  Available to comply with study protocol and sign informed consent.

        Exclusion Criteria:

          -  Patients diagnosed with COVID-19 not admitted to hospital.

          -  Patients unable to provide informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fausto J Pinto, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine of Universidade de Lisboa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Conceição Calhau, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NOVA Medical School of Universidade NOVA de Lisboa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana Freitas, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HeartGenetics SA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tiago Guimarães, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine of the University of Porto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fausto J Pinto, PhD</last_name>
    <phone>00351217985113</phone>
    <email>faustopinto@medicina.ulisboa.pt</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Conceição Calhau, PhD</last_name>
    <phone>00351218803035</phone>
    <phone_ext>20401</phone_ext>
    <email>ccalhau@nms.unl.pt</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiovascular Center at Universidade de Lisboa</name>
      <address>
        <city>Lisbon</city>
        <state>Lisboa</state>
        <zip>1649-032</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <contact>
      <last_name>Fausto J Pinto, PhD</last_name>
      <phone>00351217985113</phone>
      <email>faustopinto@medicina.ulisboa.pt</email>
    </contact>
    <contact_backup>
      <last_name>Fátima Casaca, BSc</last_name>
      <phone>00351210008500</phone>
      <email>CCUL@medicina.ulisboa.pt</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Universitário Lisboa Norte</name>
      <address>
        <city>Lisbon</city>
        <state>Lisboa</state>
        <zip>1649-032</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <contact>
      <last_name>Fausto Pinto, PhD</last_name>
      <phone>00351217985113</phone>
      <email>faustopinto@medicina.ulisboa.pt</email>
    </contact>
    <investigator>
      <last_name>Melo Cristino, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Miranda, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Helena Proença, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fausto J Pinto, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de São João</name>
      <address>
        <city>Oporto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <contact>
      <last_name>Tiago Guimarães, PhD</last_name>
      <email>jtguimar@med.up.pt</email>
    </contact>
    <investigator>
      <last_name>Tiago Guimarães, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 26, 2020</study_first_submitted>
  <study_first_submitted_qc>April 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2020</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Lisbon</investigator_affiliation>
    <investigator_full_name>Fausto J. Pinto</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Vitamin D polymorphisms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

